Brentuximab is a monoclonal antibody that specifically targets CD30, a cell surface antigen. This antibody is conjugated with monomethyl auristatin E (MMAE), resulting in the antibody-drug conjugate known as Brentuximab vedotin. This conjugate has been shown to induce apoptosis in primary effusion lymphoma cells and demonstrates potent antitumor activity. In vitro studies reveal that Brentuximab vedotin has an IC50 of 10 nM against human CD30-positive cancer cells, highlighting its efficacy in targeting and eliminating malignant cells expressing CD30.
Brentuximab is a monoclonal antibody that specifically targets CD30, a cell surface antigen. This antibody is conjugated with monomethyl auristatin E (MMAE), resulting in the antibody-drug conjugate known as Brentuximab vedotin. This conjugate has been shown to induce apoptosis in primary effusion lymphoma cells and demonstrates potent antitumor activity. In vitro studies reveal that Brentuximab vedotin has an IC50 of 10 nM against human CD30-positive cancer cells, highlighting its efficacy in targeting and eliminating malignant cells expressing CD30.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
